These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 30734088)

  • 1. Duration of anticoagulant therapy and VTE recurrence in patients with cancer.
    Khorana AA; McCrae KR; Milentijevic D; Fortier J; Nelson WW; Laliberté F; Crivera C; Lefebvre P; Schein J
    Support Care Cancer; 2019 Oct; 27(10):3833-3840. PubMed ID: 30734088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incremental health care resource utilization and economic burden of venous thromboembolism recurrence from a U.S. payer perspective.
    Lin J; Lingohr-Smith M; Kwong WJ
    J Manag Care Pharm; 2014 Feb; 20(2):174-86. PubMed ID: 24456319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. One-year adherence to warfarin treatment for venous thromboembolism in high-risk patients and its association with long-term risk of recurrent events.
    Chen SY; Wu N; Gulseth M; LaMori J; Bookhart BK; Boulanger L; Fields L; Schein J
    J Manag Care Pharm; 2013 May; 19(4):291-301. PubMed ID: 23627575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between anticoagulant treatment duration and risk of venous thromboembolism recurrence and bleeding in clinical practice.
    Kaatz S; Fu AC; AbuDagga A; LaMori J; Bookhart BK; Damaraju CV; Tan H; Schein J; Nutescu E
    Thromb Res; 2014 Oct; 134(4):807-13. PubMed ID: 25127013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Weekly risk of venous thromboembolism recurrence in patients receiving oral anticoagulants.
    Laliberté F; Coleman CI; Bookhart B; Lefebvre P; Cloutier M; Damaraju CV; Schein JR; Kaatz S
    Curr Med Res Opin; 2014 Aug; 30(8):1513-20. PubMed ID: 24738644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism.
    Coleman CI; Bunz TJ; Turpie AGG
    Thromb Haemost; 2017 Oct; 117(10):1841-1847. PubMed ID: 28640322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Healthcare resource utilization and costs associated with venous thromboembolism recurrence in patients with cancer.
    Khorana AA; McCrae KR; Milentijevic D; Laliberté F; Lejeune D; Crivera C; Lefebvre P
    J Med Econ; 2020 Apr; 23(4):323-329. PubMed ID: 31818164
    [No Abstract]   [Full Text] [Related]  

  • 8. Risk of recurrent venous thromboembolism in patients with HIV infection: A nationwide cohort study.
    Rokx C; Borjas Howard JF; Smit C; Wit FW; Pieterman ED; Reiss P; Cannegieter SC; Lijfering WM; Meijer K; Bierman W; Tichelaar V; Rijnders BJA;
    PLoS Med; 2020 May; 17(5):e1003101. PubMed ID: 32407386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hormonal contraceptive use after a first venous thrombotic event and the risk of recurrence in premenopausal women.
    Verlaan JPL; Stegeman BH; Timp JF; Scheres LJJ; Flinterman LE; Helmerhorst FM; Rosendaal FR; Cannegieter SC; van Hylckama Vlieg A
    J Thromb Haemost; 2024 Aug; 22(8):2195-2202. PubMed ID: 38554933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal duration of Vitamin K antagonists anticoagulant therapy after venous thromboembolism: a systematic review and network meta-analysis of randomized controlled trials.
    Wang W; Su Y; Wu C; Sun Y; Dai N; Chen W; Zhang J; Xu Y; Brindis RG; Xu D; Li J
    BMC Cardiovasc Disord; 2020 Feb; 20(1):53. PubMed ID: 32013892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of recurrence of cancer-associated venous thromboembolism after discontinuation of anticoagulant therapy: a multicenter cohort study.
    Lapébie FX; Bura-Rivière A; Espitia O; Bongard V; Ciammaichella MM; Martínez JG; Sigüenza P; Giménez JC; Bertoletti L; Monreal M
    J Thromb Haemost; 2023 Aug; 21(8):2189-2201. PubMed ID: 37068594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is Adherence to the American College of Chest Physicians Recommended Anticoagulation Treatment Duration Associated With Different Outcomes Among Patients With Venous Thromboembolism?
    Spyropoulos AC; Preblick R; Kwong WJ; Lingohr-Smith M; Lin J
    Clin Appl Thromb Hemost; 2017 Sep; 23(6):532-541. PubMed ID: 27899520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and safety of rivaroxaban versus warfarin in patients with provoked venous thromboembolism.
    Coleman CI; Turpie AGG; Bunz TJ; Beyer-Westendorf J
    J Thromb Thrombolysis; 2018 Oct; 46(3):339-345. PubMed ID: 29881958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Risk factors of venous thromboembolism recurrence and the predictive value of simplified pulmonary embolism severity index in medical inpatients].
    Shi CL; Zhou HX; Tang YJ; Wang L; Yi Q; Liang ZA
    Zhonghua Yi Xue Za Zhi; 2016 Apr; 96(14):1112-5. PubMed ID: 27095779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utilization of parenteral anticoagulants and warfarin: impact on the risk of venous thromboembolism recurrence in the outpatient setting.
    Cai J; Preblick R; Zhang Q; Kwong WJ
    Am Health Drug Benefits; 2014 Nov; 7(8):444-51. PubMed ID: 25558306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Venous Thromboembolism Recurrence in Latvian Population: Single University Hospital Data.
    Ģībietis V; Kigitoviča D; Strautmane S; Meilande K; Kalējs VR; Zaičenko A; Maķe K; Lejnieks A; Skride A
    Medicina (Kaunas); 2019 Aug; 55(9):. PubMed ID: 31438542
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical characteristics and treatment patterns of patients with venous thromboembolism (VTE) transitioning from hospital to post-discharge settings.
    Burton T; Hlavacek P; Guo JD; Rosenblatt L; Mardekian J; Ferri M; Russ C; Kline JA
    Hosp Pract (1995); 2020 Oct; 48(4):196-205. PubMed ID: 32720816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Outcomes of Incidental Venous Thromboembolism in Cancer and Noncancer Patients: The SWIss Venous ThromboEmbolism Registry (SWIVTER).
    Spirk D; Sebastian T; Barco S; Banyai M; Beer JH; Mazzolai L; Baldi T; Aujesky D; Hayoz D; Engelberger RP; Kaeslin T; Korte W; Escher R; Husmann M; Blondon M; Kucher N
    Thromb Haemost; 2021 May; 121(5):641-649. PubMed ID: 33202448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome after discontinuing anticoagulant therapy in women with venous thromboembolism during hormonal use.
    Blanco-Molina Á; Trujillo-Santos J; Pesavento R; Rosa V; Falgá C; Tolosa C; Mazzolai L; Sampériz Á; Duce R; Monreal M;
    Thromb Res; 2017 Mar; 151 Suppl 1():S6-S10. PubMed ID: 28262237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The risk for fatal pulmonary embolism after discontinuing anticoagulant therapy for venous thromboembolism.
    Douketis JD; Gu CS; Schulman S; Ghirarduzzi A; Pengo V; Prandoni P
    Ann Intern Med; 2007 Dec; 147(11):766-74. PubMed ID: 18056660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.